Edition:
United States

Analyst Research

Report Title Price
Provider : Wright Reports
$75.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

La Jolla Pharmaceutical Co announces positive pre-clinical data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis


Tuesday, 15 Jul 2014 08:00am EDT 

La Jolla Pharmaceutical Co:Announces positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH).LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial.La Jolla Pharmaceutical Company intends to file an Investigational New Drug application and initiate a Phase 1/2 clinical trial in NASH in the first half of 2015. 

Company Quote

15.44
 --
26 May 2016